Detail akcie BB Biotech AG online

Business Summary: BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, BB BIOTECH AG revenues increased from SF112.2M to SF616.7M. Net income increased from SF75.9M to SF578.1M. Revenues reflect Unrealized Gains/Losses on Securities increase from SF50.1M to SF539.9M, Realized G/L on Securities increase of 21% to SF74.2M, Other income increase from SF6K to SF1.3M. Net income benefited from Management fees decrease of 14% to SF21.5M (expense).